TGTX Net Receivables from 2010 to 2025

TGTX Stock  USD 29.55  0.41  1.41%   
TG Therapeutics Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2025. During the period from 2010 to 2025, TG Therapeutics Net Receivables regression line of annual values had r-squared of  0.47 and arithmetic mean of  10,873,382. View All Fundamentals
 
Net Receivables  
First Reported
1998-06-30
Previous Quarter
83.6 M
Current Value
115.7 M
Quarterly Volatility
22.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 510.8 K, Interest Expense of 15.2 M or Total Revenue of 282.1 M, as well as many indicators such as Price To Sales Ratio of 8.87, Dividend Yield of 4.0E-4 or PTB Ratio of 14.28. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of TG Therapeutics over the last few years. It is TG Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

TGTX Net Receivables Regression Statistics

Arithmetic Mean10,873,382
Geometric Mean0.00
Coefficient Of Variation212.12
Mean Deviation17,365,575
Median95,000
Standard Deviation23,064,541
Sample Variance532T
Range61.7M
R-Value0.68
Mean Square Error303.5T
R-Squared0.47
Significance0
Slope3,312,232
Total Sum of Squares7979.6T

TGTX Net Receivables History

202561.7 M
202458.8 M
202351.1 M
20211.4 M
2019null
201895 K
2017108.5 K

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables58.8 M61.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.